search
data pipelines
Trends
- 1
Evotec, the Hamburg-based drug discovery company, is highlighting how it pairs human scientific expertise with artificial intelligence across its research pipelines. The message underscores a growing theme in biotech: AI models are powerful tools, but experienced scientists remain essential to interpret data and guide drug development decisions.
- 2Cursor staff probed whether confidential data reached SpaceX for AI training▼Cursor Staff Investigated Whether Confidential Data Reached SpaceX for AI Training
Anycursor, the company behind the AI code editor Cursor, reportedly had staff investigate whether confidential customer data ended up with SpaceX for use in AI training. The claim was reported by The Information. If confirmed, it would raise serious questions about how sensitive developer and enterprise code is handled by AI vendors and their cloud partners.
- 3Mexico Revises Renewable Pipeline: 42 Solar, 13 Wind Projects▼Mexico Revises Renewable Pipeline: 42 Solar, 13 Wind Projects - News and Statistics
Mexico has updated its national renewable energy project pipeline, which now includes 42 solar and 13 wind projects, according to industry data tracking. The revision offers a snapshot of planned clean-power capacity across the country and comes as interest grows in how quickly Mexico is expanding renewable generation. Observers are watching the figures for signals about investment direction in the sector.
- 4Editas Medicine to Present Gene-Editing Data at ESGCT Congress●Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Editas Medicine said it will present posters at the European Society of Gene and Cell Therapy's 33rd Annual Congress and take part in an upcoming investor conference. The gene-editing company did not disclose further details in the announcement, and no data summaries or pipeline updates were included with the initial notice.
- 5Aulos Bioscience to Present Phase 2 Lung Cancer Data at ESMO 2026●Aulos Bioscience to Present Phase 2 Data for Imneskibart With Avelumab in Adenocarcinoma Non-Small Cell Lung Cancer at ESMO Congress 2026
Aulos Bioscience will present Phase 2 clinical trial data for imneskibart, used in combination with avelumab, in patients with adenocarcinoma non-small cell lung cancer at the ESMO Congress 2026. The announcement signals a key data readout for the company's oncology pipeline, with the findings likely to draw attention from investors and the cancer research community ahead of the congress.